Clinical trials: 5-FU
Squamous Cell Carcinoma of Skin, Carcinoma, Squamous Cell
Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
The purpose of this study is to find out if the combination of two established anti-cancer therapies are beneficial in patients with squamous cell carcinoma of the skin.
- Trial name
- NCT02218164
- Testing
- Pegylated Interferon alpha-2b, Capecitabine, 5-FU
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Cancer, Pancreas Cancer
Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
Given the efficacy of nanoliposomal irinotecan as a second-line regimen in pancreatic ductal adenocarcinoma (PDAC), together with the favorable toxicity profile of paricalcitol and its interplay with irinotecan metabolism, the…
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas
- Trial name
- NCT03883919
- Testing
- 5-FU, Leucovorin, Liposomal Irinotecan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Neck Cancer
Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer
patients with locally advanced cancer of oropharynx, hypopharynx or larynx and CPS>1 will recieve 3 cycles of induction immunochemotherapy with platinum, 5-FU and pembrolizumab followed by (chemo)radiation.
- Trial name
- NCT05551767
- Testing
- Pembrolizumab
- Where
- 3 sites in Russia
- Volunteers
- 120 people
- Sponsor
- City Clinical Oncology Hospital No 1
Advanced Solid Tumours
Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer
The purpose of this study is to determine whether AZD0156 is safe, what is the best dose to give, and how it is processed by the body when given alone or in combination with other agents.
- Trial name
- AToM (NCT02588105)
- Testing
- AZD0156, Olaparib, irinotecan
- Where
- 5 sites in United States, South Korea and 2 more
- Volunteers
- 84 people
- Sponsor
- AstraZeneca
Metastatic Pancreatic Cancer
First-line Therapy in Metastatic PDAC
The overarching hypothesis of this trial is that the NAPOLI regimen and alternating cycles of NAPOLI and mFOLFOX6 (seq-NAPOLI-FOLFOX) are superior to the current standard of care gemcitabine/nab-paclitaxel.
- Trial name
- FOOTPATH (NCT03487016)
- Testing
- Gemcitabine, Nab-paclitaxel, 5-FU
- Where
- Germany
- Volunteers
- 270 people
- Sponsor
- Ludwig-Maximilians - University of Munich
PreDiabetes, Metabolic Management Center
Prediabetes Management
Systematically screen the high-risk population of diabetes in Xinqiao district to understand the characteristics of early glucose metabolism changes and pancreatic islet function changes in patients with pre diabetes.
- Conditions
- PreDiabetes, Metabolic Management Center, Continuous Glucose Monitoring
- Trial name
- NCT05531838
- Testing
- Fu Lishan instant sense hospital dynamic glucose monitoring system
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
This pilot phase II trial studies how well giving bevacizumab and combination chemotherapy together before surgery works in treating patients with locally advanced esophageal or stomach cancer.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT01212822
- Testing
- bevacizumab, oxaliplatin, leucovorin calcium
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fox Chase Cancer Center
ESCC or Esophageal Adenosquamous Carcinoma
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC
This study is conducted in patients with Locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma (ESCC) or esophageal adenosquamous carcinoma. This study includes three arms: A, B1, and B2.
- Trial name
- NCT05221658
- Testing
- HLX07+HLX10+ Cisplatin+5-FU, HLX07
- Where
- 17 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai Henlius Biotech
Early Childhood Caries, Oral Hygiene
Acceptance and Efficacy of a Digital Application Among Parents to Control Early Childhood Caries
Few educational oral health applications, directed to the preschool children under the age of six years are available world-wide.
- Conditions
- Early Childhood Caries, Oral Hygiene, Oral Health
- Trial name
- FU-APP (NCT05515510)
- Testing
- FU-APP, Oral health recommendations
- Where
- Germany
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Metastatic Biliary Tract Cancer
Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer
The purpose of this study is to evaluate the efficacy and safety of combination of fluorouracil/folinic acid and liposomal irinotecan(Onivyde) compared with fluoruracil/folinic acid in patients with metastatic biliary tract…
- Trial name
- NCT03524508
- Testing
- Onivyde, 5-FU/LV
- Where
- South Korea
- Volunteers
- 178 people
- Sponsor
- Changhoon Yoo
Breast Cancer
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, epirubicin, cyclophosphamide, and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087178
- Testing
- cyclophosphamide, adriamycin, epirubicin
- Where
- 606 sites in United States, Canada and 1 more
- Volunteers
- 2,722 people
- Sponsor
- NSABP Foundation Inc
Colorectal Cancer
Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00280761
- Testing
- capecitabine, 5-fluorouracil, Surgical Resection
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
This is a study of pembrolizumab (MK-3475) for advanced gastric or gastroesophageal junction adenocarcinoma; pembrolizumab will be given as monotherapy to participants who have had previous treatment or who are treatment-naïve…
- Trial name
- NCT02335411
- Testing
- pembrolizumab, cisplatin, 5-FU
- Volunteers
- 318 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Pancreatic Cancer
BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
A standard treatment for your cancer is called FOLFIRINOX (this utilizes the FDA approved chemotherapy drugs fluorouracil, leucovorin, oxaliplatin and irinotecan).
- Trial name
- NCT02080221
- Testing
- FOLFOXA
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Brown University
Esophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
This is a single-arm，open-label study to evaluate the efficacy and safety of tislelizumab plus chemotherapy for conversion therapy of patients with locally nonresectable ESCC.
- Trial name
- NCT05469061
- Testing
- Tislelizumab, 5-FU, cis Platinum
- Where
- China
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer
A Prospective, Single Center Clinical Study of Toripalimab Combined With FLOT Regimen for Perioperative Treatment of PD-L1 Positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GEJ)
In this study, patients with PD-L1 positive locally advanced patients with resectable gastric cancer or gastroesophageal junction adenocarcinoma were invited to participate in the study.To evaluate the efficacy and safety of…
- Trial name
- NCT05466019
- Testing
- Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Hospital of Jilin University
Stomach Cancer, Gastroesophageal Junction Cancer
FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)
Previous studies provide a strong theoretical rationale for the conduct of a randomized study evaluating the efficacy and safety of ramucirumab in combination with FLOT in the perioperative treatment of resectable adenocarcinoma…
- Trial name
- RAMSES/FLOT7 (NCT02661971)
- Testing
- Docetaxel, Oxaliplatin, Calciumfolinat
- Where
- 2 sites in Germany, Italy
- Volunteers
- 180 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Temporal Bone Squamous Cell Carcinoma
A Prospective, Single-arm Clinical Study of Pabrolizumab in Combination With Cisplatin + 5-FU for the Neoadjuvant Treatment of Unresectable, Advanced Squamous Carcinoma of the Temporal Bone Single-arm Clinical Study
Temporal bone cancer accounts for 0.2% of head and neck cancers. Advanced temporal bone cancer often involves structures such as apices, internal carotid artery canals, and dura mater, and negative margins cannot be obtained…
- Trial name
- NCT05444673
- Testing
- Paprizumab combined with cisplatin and 5-FU
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nasopharyngeal Carcinoma, TNF
A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC
Based on the application prospect of rmh-TNF combined with chemotherapy in the treatment of solid tumors. In this study, cisplatin combined with low dose 5-FU was proposed to enhance the immune function of 5-FU.
- Conditions
- Nasopharyngeal Carcinoma, TNF, Chemo-radiotherapy
- Trial name
- NCT05433597
- Testing
- 5-fu, Cisplatin, Radiotherapy
- Volunteers
- 172 people
- Sponsor
- Sun Yat-sen University
Esophageal Cancer, Adenocarcinoma of the Esophagus
Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
OncoGel is a new experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel) over a long period of time.
- Conditions
- Esophageal Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma
- Trial name
- NCT00573131
- Testing
- OncoGel (Paclitaxel gel), cisplatin, 5-FU
- Where
- 20 sites in United States, Czechia and 2 more
- Volunteers
- 137 people
- Sponsor
- Boston Scientific Corporation